Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candoxatril SCHEMBL121666 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL29494166 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL1649937 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL5601069 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL14660450 | 0.98 | MME (0.95) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL9470376 | 0.94 | MME (0.88) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL16624679 | 0.92 | MME (0.85) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL7322664 | 0.91 | MME (0.83) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL7329974 | 0.91 | MME (0.83) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL9469895 | 0.89 | MME (0.80) | MMEPPARGPPARDKDM4EPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | claimed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | claimed |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| JP-4820056-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| US-20080261958-A1 | Combination of Organic Compounds | WEBB RANDY LEE | 2008-10-23 | — | — | US | claimed |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | WEBB RANDY LEE | 2008-05-22 | — | — | US | claimed |
| EP-1863467-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2007045663-A2 | COMBINATION OF AN ATI RECEPTOR ANTAGONIST AND A NP INHIBITOR FRO TREATING IA HYPERTENSION AND HEARTFAILURE | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | claimed |
| WO-2006086456-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-1467728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | Novartis AG (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003059345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | claimed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | claimed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | claimed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | claimed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | claimed |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | MME, REN, AGTR1 | MME 1/4885PPARG 2192/4885PPARD 1437/4885 |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | MME 2/4885PPARG 1442/4885PPARD 1623/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885PPARG 2492/4885PPARD 2638/4885 |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | MME, DNPEP, AGTR1 | MME 1/4885PPARG 1684/4885PPARD 1690/4885 |
| US-20080261958-A1 | Combination of Organic Compounds | REN, MME, ACE | MME 2/4885PPARG 2226/4885PPARD 1446/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885PPARG 2492/4885PPARD 2638/4885 |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | REN, AGTR1, AGTR2 | MME 4/4885PPARG 1370/4885PPARD 1286/4885 |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | MME, REN, ACE | MME 1/4885PPARG 2656/4885PPARD 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.